Editorial: Autoimmune and inflammatory rheumatic diseases: Identifying biomarkers of response to therapy with biologics: Volume II.
作者信息
Giuliani Anna Lisa, Bortoluzzi Alessandra, Oliviero Francesca
机构信息
Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
Department of Medicine, DIMED, University of Padua, Padua, Veneto, Italy.
出版信息
Front Pharmacol. 2023 Feb 28;14:1164723. doi: 10.3389/fphar.2023.1164723. eCollection 2023.
Abstract
摘要
相似文献
1
Editorial: Autoimmune and inflammatory rheumatic diseases: Identifying biomarkers of response to therapy with biologics: Volume II.社论：自身免疫性和炎性风湿性疾病：确定生物制剂治疗反应的生物标志物：第二卷。
Front Pharmacol. 2023 Feb 28;14:1164723. doi: 10.3389/fphar.2023.1164723. eCollection 2023.
2
Editorial: Autoimmune and Inflammatory Rheumatic Diseases: Identifying Biomarkers of Response to Therapy With Biologics.社论：自身免疫性和炎性风湿性疾病：确定生物制剂治疗反应的生物标志物
Front Pharmacol. 2021 Dec 10;12:815656. doi: 10.3389/fphar.2021.815656. eCollection 2021.
3
Biologics and risk of tuberculosis in autoimmune rheumatic diseases: A real-world clinical experience from India.生物制剂与自身免疫性风湿疾病中的结核病风险：来自印度的真实世界临床经验
Int J Rheum Dis. 2019 Feb;22(2):280-287. doi: 10.1111/1756-185X.13376. Epub 2018 Aug 30.
4
Biologic therapies in non-rheumatic diseases: lessons for rheumatologists?生物制剂在非风湿性疾病中的应用：对风湿病医生的启示？
Nat Rev Rheumatol. 2011 Aug 2;7(9):507-16. doi: 10.1038/nrrheum.2011.106.
5
[Safety and efficacy of off-label use of biologic therapies in patients with inflammatory rheumatic diseases refractory to standard of care therapy : Data from a nationwide German registry (GRAID2)].[生物疗法在标准治疗难治性炎症性风湿病患者中的超说明书使用的安全性和有效性：来自德国全国性登记处（GRAID2）的数据]
Z Rheumatol. 2018 Feb;77(1):28-39. doi: 10.1007/s00393-017-0330-4.
6
Circulating Calprotectin (cCLP) in autoimmune diseases.循环钙卫蛋白（cCLP）与自身免疫性疾病。
Autoimmun Rev. 2023 May;22(5):103295. doi: 10.1016/j.autrev.2023.103295. Epub 2023 Feb 11.
7
Vitamin D deficiency in patients with either rheumatic diseases or inflammatory bowel diseases on biologic therapy.接受生物治疗的风湿性疾病或炎症性肠病患者的维生素D缺乏症。
Intern Emerg Med. 2016 Sep;11(6):803-7. doi: 10.1007/s11739-016-1415-9. Epub 2016 Mar 3.
8
Immune-regulatory mechanisms in systemic autoimmune and rheumatic diseases.系统性自身免疫性疾病和风湿性疾病中的免疫调节机制。
Clin Dev Immunol. 2012;2012:941346. doi: 10.1155/2012/941346. Epub 2011 Oct 27.
9
Biologics During Pregnancy and Breastfeeding Among Women With Rheumatic Diseases: Safety Clinical Evidence on the Road.患有风湿性疾病的女性在孕期和哺乳期使用生物制剂：前行中的安全性临床证据。
Front Pharmacol. 2021 Feb 11;12:621247. doi: 10.3389/fphar.2021.621247. eCollection 2021.
10
Safety of Biologic Therapy in Older Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis.老年免疫性疾病患者接受生物治疗的安全性：系统评价和荟萃分析。
Clin Gastroenterol Hepatol. 2019 Aug;17(9):1736-1743.e4. doi: 10.1016/j.cgh.2018.12.032. Epub 2019 Jan 4.
本文引用的文献
1
Synovial Fluid Analysis to Identify Osteoarthritis.滑液分析可用于诊断骨关节炎。
J Vis Exp. 2022 Oct 20(188). doi: 10.3791/64351.
2
Treatment Guidelines in Rheumatoid Arthritis.类风湿关节炎治疗指南
Rheum Dis Clin North Am. 2022 Aug;48(3):679-689. doi: 10.1016/j.rdc.2022.03.005. Epub 2022 Jul 5.
3
One year in review 2022: systemic lupus erythematosus.2022 年回顾：系统性红斑狼疮。
Clin Exp Rheumatol. 2022 Jan;40(1):4-14. doi: 10.55563/clinexprheumatol/nolysy. Epub 2022 Jan 28.
4
Idiopathic inflammatory myopathies.特发性炎性肌病
Nat Rev Dis Primers. 2021 Dec 2;7(1):86. doi: 10.1038/s41572-021-00321-x.
5
Pathophysiology of systemic sclerosis.系统性硬化症的病理生理学。
Presse Med. 2021 Apr;50(1):104087. doi: 10.1016/j.lpm.2021.104087. Epub 2021 Oct 28.
6
Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis.类风湿性关节炎治疗的有前途的治疗靶点。
Front Immunol. 2021 Jul 9;12:686155. doi: 10.3389/fimmu.2021.686155. eCollection 2021.
7
Traditional herbal medicine: Therapeutic potential in rheumatoid arthritis.传统草药：类风湿关节炎的治疗潜力。
J Ethnopharmacol. 2021 Oct 28;279:114368. doi: 10.1016/j.jep.2021.114368. Epub 2021 Jun 29.
8
Osteoimmunological insights into the pathogenesis of ankylosing spondylitis.骨免疫学对强直性脊柱炎发病机制的见解。
J Cell Physiol. 2021 Sep;236(9):6090-6100. doi: 10.1002/jcp.30313. Epub 2021 Feb 8.
9
Association between XRCC3 Thr241Met polymorphism and risk of gynecological malignancies: A meta-analysis.XRCC3 Thr241Met 多态性与妇科恶性肿瘤风险的关联：一项荟萃分析。
Cancer Genet. 2021 Jun;254-255:11-17. doi: 10.1016/j.cancergen.2021.01.003. Epub 2021 Jan 13.
10
State-of-the-art treatment of systemic lupus erythematosus.系统性红斑狼疮的最新治疗方法。
Int J Rheum Dis. 2020 Apr;23(4):465-471. doi: 10.1111/1756-185X.13817. Epub 2020 Mar 5.
Zotero 插件